about chromovertOverview The discovery of new drugs is the process by which compounds are found that have specific desired activity against a therapeutic target. Since the early 1990s, high-throughput screening of diverse chemical compound libraries has been the usual initial step in drug discovery. In recent years, cell-based assay systems have become routine for primary compound screening. Since traditional cell production is a manual and time-consuming process, the cell lines used for these screens were usually limited to those expressing a single gene, such as one subunit of a heteromeric target. Chromovert® technology overcomes this fundamental obstacle to effective cell-based screening. We are able to identify and isolate out of millions of analyzed cells the rare clone stably expressing multiple genes of interest that comprise a complete physiological target. This allows us to do high-throughput screening with unparalleled results.
Chromocell is engaged in the discovery and development of therapeutic compounds against the most complex and challenging drug targets. We focus on projects that require multi-gene cell lines or large panels of related receptors, where the use of Chromovert technology provides a competitive advantage.
Chromocell is an integrated drug discovery company with leading expertise and abilities in molecular and cell biology, assay development, high-throughput screening and medicinal chemistry.
